Eli Lilly and Company $LLY Stock Holdings Increased by Sarasin & Partners LLP

Key Points

• Sarasin & Partners LLP increased its holdings in Eli Lilly and Company by 4.3% during the 2nd quarter, purchasing an additional 9,735 shares, bringing their total to 237,793 shares valued at $185,367,000.
• Several other institutional investors also raised their positions in Eli Lilly, contributing to the overall institutional ownership of 82.53% of the stock.
• Eli Lilly's quarterly earnings report showed an EPS of $6.31, exceeding estimates by $0.72, with revenue of $15.56 billion, representing a year-over-year increase of 37.6%.

Sarasin & Partners LLP grew its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.3% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 237,793 shares of the company's stock after buying an additional 9,735 shares during the quarter. Eli Lilly and Company accounts for approximately 1.8% of Sarasin & Partners LLP's portfolio, making the stock its 23rd biggest position. Sarasin & Partners LLP's holdings in Eli Lilly and Company were worth $185,367,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in LLY. PNC Financial Services Group Inc. lifted its stake in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after buying an additional 50,002,551 shares during the last quarter. GAMMA Investing LLC lifted its stake in Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after buying an additional 14,852,076 shares during the last quarter. Nuveen LLC purchased a new stake in Eli Lilly and Company in the first quarter valued at approximately $4,613,912,000. Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after buying an additional 4,975,395 shares during the last quarter. Finally, Cohen Investment Advisors LLC lifted its stake in Eli Lilly and Company by 7,975.5% in the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock valued at $647,225,000 after buying an additional 773,947 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity

In other Eli Lilly and Company news, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 over the last quarter. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Trading Down 1.2%

Shares of Eli Lilly and Company stock traded down $9.41 during trading hours on Friday, reaching $753.52. The stock had a trading volume of 7,319,147 shares, compared to its average volume of 3,181,974. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $939.86. The firm has a market capitalization of $713.18 billion, a price-to-earnings ratio of 49.25, a P/E/G ratio of 1.06 and a beta of 0.47. The firm has a 50 day simple moving average of $738.37 and a two-hundred day simple moving average of $771.89.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the firm earned $3.92 earnings per share. The company's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on LLY. Cantor Fitzgerald cut their price target on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research note on Wednesday, August 13th. UBS Group cut their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Wall Street Zen cut Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.